Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study assessing
the efficacy and safety of lenabasum for the treatment of dermatomyositis. Approximately 150
subjects will be enrolled in this study at about 60 sites in North America, Europe, and Asia.
The planned duration of double-blind treatment with study drug is up to 52 weeks.